Showing 7011-7020 of 7734 results for "".
- Game Change: The New Global Psoriasis Atlas to Accrue Worldwide PsO Datahttps://practicaldermatology.com/news/game-change-the-new-global-psoriasis-atlas-to-accrue-worldwide-pso-data/2458419/Three global health organizations are joining forces to launch the Global Psoriasis Atlas (GPA), the first-ever worldwide database on psoriasis. The GPA project comes in response to the 2016 World Health Organization (WHO) Global Report on
- Regeneron and Sanofi's Dupilumab Biologics License Application Accepted for Priority Review by FDAhttps://practicaldermatology.com/news/regeneron-and-sanofis-dupilumab-biologics-license-application-accepted-for-priority-review-by-fda/2458423/The FDA has accepted for priority review the Biologics License Application (BLA) for dupilumab from Regeneron Pharmaceuticals, Inc. and Sanofi for the treatment of adult patients with inadequately controlled moderate-to-severe atopic dermatitis (AD). The application has been given a Prescription
- Stelara Adds New Approval: Crohn's Diseasehttps://practicaldermatology.com/news/stelara-adds-new-approval-crohns-disease/2458422/The FDA has approved STELARA® (ustekinumab) from Janssen Biotech, Inc., for the treatment of moderately to severely active Crohn’s disease in adults (18 years or older) who have failed or were intolerant to treatment with immunomodulators or corticost
- FDA Approves Humira Biosimilarhttps://practicaldermatology.com/news/fda-approves-humira-biosimilar/2458424/The U.S. Food and Drug Administration today approved Amjevita (adalimumab-atto) as a biosimilar to Humira (adalimumab) for multiple inflammatory diseases. Amjevita is approved for the following indications in adult patients: ·  
- Launches, Anniversaries and More: Aesthetic News from Around the Webhttps://practicaldermatology.com/news/launches-anniversaries-and-more-aesthetic-news-from-around-the-web/2458425/RealSelf Rolls Out RealSelf Business Pages RealSelf is launching of RealSelf Business Pages so doctors can showcase the full range of providers at a practice as well as the tr
- Research Elucidates Skin Phenotype of Pediatric Eczemahttps://practicaldermatology.com/news/research-elucidates-skin-phenotype-of-pediatric-eczema/2458426/Pediatric atopic dermatitis (AD) in infants looks a lot different than adult AD, suggesting the need for alternative, and possibly more aggressive, treatment strategies in children. The study, led by researchers at the Icahn School of Medicine at Mount Sina
- Novan, Inc. Launches IPO, Lists on NASDAQhttps://practicaldermatology.com/news/novan-inc-launches-ipo-lists-on-nasdaq/2458429/Novan, Inc. (the “Company” or “Novan”) today announced the pricing of the Company’s initial public offering of 4,100,000 shares of common stock at a price to the public of $11.00 per share. The common stock of Novan has been approved for listing on the NASDAQ Global
- Orphan Drug Designation Granted to Nintedanib for Systemic Sclerosishttps://practicaldermatology.com/news/orphan-drug-designation-granted-to-nintedanib-for-systemic-sclerosis/2458441/The European Commission (EC) and the FDA have granted Orphan Drug Designation to Boehringer Ingelheim's nintedanib for the treatment of systemic sclerosis (SSc, also known as scleroderma), including the associated interstitial lung disease (SSc-ILD).
- Cetaphil® Marks Fifth Year of Support for CSDF and Camp Wonderhttps://practicaldermatology.com/news/cetaphil-marks-fifth-year-of-support-for-csdf-and-camp-wonder/2458452/Galderma Laboratories, L.P., makers of Cetaphil, is celebrating the fifth consecutive year of its "Meaningphil™" partnership with the Children's Skin Disease Foundation (CSDF) and Camp Wonder.</
- Cloudy with a Chance of Wrinkles: ROC Ranks US Cities By Wrinkle Indexhttps://practicaldermatology.com/news/cloudy-with-a-chance-of-wrinkles-roc-ranks-cities-by-wrinkle-index/2458453/Philadelphia will be the most wrinkle-prone city in America come 2040 thanks to high stress levels, more airborne pollution, lengthy commute times and higher than average smoking rates, according to the 2016 RoC® Wrinkle Ranking. San Jose, Calif. will hold the least wrinkle-pron